ERBB2 and breast carcinoma: Given the diverse clinical scenarios in HER2-positive breast cancer, including neoadjuvant, adjuvant, and metastatic settings, this review aims to systematically evaluate the efficacy and safety of combining pertuzumab, trastuzumab, and docetaxel.